Evolocumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Evolocumab and local guidelines before prescribing.
PCSK9 inhibitor
Mechanism
PCSK9 inhibitor monoclonal antibody.
Uses
Familial hypercholesterolaemia, high-risk patients not at LDL target on maximal therapy.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Injection-site reactions, nasopharyngitis, influenza-like illness.
Interactions
Few.
Contraindications and cautions
Hypersensitivity
Monitoring
Lipids
Pregnancy and breastfeeding
Avoid unless essential
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Subcutaneous every 2 or 4 weeks; used per NICE criteria.
More from the textbook: uses, cautions and other points
- PCSK9 inhibitors - alirocumab , evolocumab (injections every 2–4 weeks); inclisiran (small interfering RNA, injection every 6 months) - large LDL reductions for high-risk or familial hypercholesterolaemia patients not at target.
Cardiology: Anatomy Physiology and Pharmacology - PCSK9 antibodies Evolocumab, alirocumab | SC every 2–4 weeks; specialist; NICE LDL thresholds.
Endocrinology: Lipids and obesity - PCSK9 inhibitors (evolocumab, alirocumab) or inclisiran if LDL remains high (NICE criteria); bempedoic acid in some.
Clinical Genetics: Cancer genetics and inherited cardiovascular conditions - LDL receptor regulation - low intracellular cholesterol (e.g. statins) → SREBP activation → more LDL receptors → lower plasma LDL. PCSK9 degrades LDL receptors - PCSK9 inhibitors (evolocumab, alirocumab) and inclisiran (siRNA) raise receptor numbers.
Biochemistry: Metabolism of carbohydrates, lipids and proteins